

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Various				
Ischemia/reperfusion injury; renal damage	Receptor-interacting serine-threonine kinase 1 (RIPK1; RIP1); cyclophilin A (CYPA; PPIA)	<p>Mouse studies suggest the ferrostatin 16-86 could help protect against ischemia/reperfusion injury and kidney damage. Ferrostatins inhibit ferroptosis, an iron-dependent form of necrosis, and protect mouse renal cells from injury-induced ferroptosis. In mouse models of injury-induced acute renal failure, 16-86 decreased organ damage compared with an inactive analog or vehicle. In mouse models of severe renal ischemia/reperfusion injury, 16-86 increased the damage-preventing effects of a combination of RIPK1 and CYPA inhibitors compared with the inactive analog. Next steps could include optimizing 16-86 and evaluating the compound in additional ischemia/reperfusion injury models.</p> <p>SciBX 7(47); doi:10.1038/scibx.2014.1387 Published online Dec. 11, 2014</p>	Patent and licensing status unavailable	<p>Linkermann, A. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Nov. 10, 2014; doi:10.1073/pnas.1415518111 Contact: Stefan Krautwald, Kiel University, Kiel, Germany e-mail: krautwald@nephro.uni-kiel.de Contact: Andreas Linkermann, same affiliation as above e-mail: andreas.linkermann@uksh.de</p>